Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$7.6 million.

  • Mangoceuticals' Income towards Parent Company fell 28099.71% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.8 million, marking a year-over-year decrease of 11253.74%. This contributed to the annual value of -$8.7 million for FY2024, which is 548.38% up from last year.
  • Latest data reveals that Mangoceuticals reported Income towards Parent Company of -$7.6 million as of Q3 2025, which was down 28099.71% from -$5.4 million recorded in Q2 2025.
  • Mangoceuticals' 5-year Income towards Parent Company high stood at -$1.8 million for Q3 2023, and its period low was -$7.6 million during Q3 2025.
  • For the 3-year period, Mangoceuticals' Income towards Parent Company averaged around -$3.3 million, with its median value being -$2.4 million (2024).
  • As far as peak fluctuations go, Mangoceuticals' Income towards Parent Company soared by 2412.15% in 2024, and later plummeted by 28099.71% in 2025.
  • Quarter analysis of 3 years shows Mangoceuticals' Income towards Parent Company stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then crashed by 290.99% to -$7.6 million in 2025.
  • Its last three reported values are -$7.6 million in Q3 2025, -$5.4 million for Q2 2025, and -$4.8 million during Q1 2025.